Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. (Q50798708)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Francesco Dazzi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jakob R. Passweg

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Alejandro Madrigal

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

23

W Wiktor-Jedrzejczak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

T Ruutu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Gratwohl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

T de Witte

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Apperley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Bacigalupo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P Dreger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

R Duarte

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Finke

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

L Garderet

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

H Greinix

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

E Holler

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

N Kröger

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Lawitschka

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

M Mohty

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Nagler

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

O Ringdén

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

G Socié

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Sierra

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Sureda

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

D Niederwieser

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

29 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

168-173

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892326%20AND%20SRC:MED&resulttype=core&format=json

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Viral disease prevention after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Methotrexate and Citrovorum Factor after Histoincompatible Allogeneic Bone Marrow Transplants in Dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Folinic acid administration following MTX as prophylaxis for GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Defining the intensity of conditioning regimens: working definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Secondary treatment of acute graft-versus-host disease: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.107

Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study

21 January 2018

1 reference

12 December 2020

A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT

1 reference

12 December 2020

Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies

1 reference

12 December 2020

Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

1 reference

12 December 2020

Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia

1 reference

12 December 2020

Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation

1 reference

12 December 2020

Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT

1 reference

12 December 2020

Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation

1 reference

12 December 2020

Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia?

1 reference

12 December 2020

Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin

1 reference

12 December 2020